PHI with Infantile spinal muscular atrophy, Werdnig-Hoffmann type
How does this condition affect your private health insurance?
Infantile Spinal Muscular Atrophy (SMA) Type 1, or Werdnig-Hoffmann disease, is the most severe form of SMA, a rare genetic neuromuscular disorder. It stems from a deficiency of the SMN1 protein, critical for motor neuron survival. Symptoms emerge within the first 6 months of life, characterized by profound muscle weakness, hypotonia (floppy baby syndrome), severe feeding and breathing difficulties, and absent reflexes. Infants struggle to lift their heads and cannot achieve developmental milestones like sitting. Progressive muscle wasting, leading to respiratory failure, is characteristic. This autosomal recessive condition often results in significant morbidity and early mortality if untreated, making early diagnosis and intervention crucial.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Progressive from birth or early infancy (within 6 months), indicating continuous symptom manifestation.
Duration of Illness (Lifetime)
Chronic, progressive, lifelong disease.
Cost of Treatment (Initial)
Extremely high (e.g., millions of USD for initial gene therapy or loading doses of other targeted treatments, plus diagnostic and initial supportive care costs).
Cost of Treatment (Lifetime)
Extremely high, encompassing initial specialized therapies, ongoing medications, extensive supportive care, physical and occupational therapy, respiratory support, and adaptive equipment; typically millions of USD.
Mortality Rate
Historically very high (over 90% by age 2 without treatment), primarily due to respiratory failure. Significantly reduced with modern therapies, but still elevated compared to the general population.
Risk of Secondary Damages
Very high, including severe respiratory insufficiency, scoliosis, joint contractures, feeding difficulties, aspiration pneumonia, and motor developmental delays.
Probability of Full Recovery
Extremely low (virtually none). Modern treatments can halt progression and improve motor function, but do not cure the underlying genetic defect or fully reverse neurological damage.
Underlying Disease Risk
Low for other unrelated primary genetic diseases. SMA Type 1 is the primary genetic disorder. However, patients commonly experience complications (e.g., recurrent respiratory infections, aspiration pneumonia) that are secondary to the disease.